A Cost-effectiveness analysis of Nivolumab plus chemotherapy for the first-line treatment of locally advanced or metastatic gastric/GEJ/oesophageal adenocarcinoma in the United States of America
Zhou, J.; Tang, Y.; Li, G.
Show abstract
BackgroundNivolumab in combination with chemotherapy significantly improves survival in patients with gastric/gastroesophageal junction (G/GEJ)/esophageal adenocarcinoma.The purpose of this study was to evaluate the cost-effectiveness of Nivolumab plus chemotherapy for G/GEJ/esophageal adenocarcinoma. MethodsA Markov model was developed on the basis of the US healthcare payers perspectives. We estimated the costs and summarised their effectiveness as quality-adjusted life-years (QALYs). One-way and probabilistic sensitivity analyses were conducted to explore the impact of uncertainties on the cost-effectivenesss results. ResultsThe incremental cost-effectiveness ratios (ICER) for Nivolumab plus chemotherapy($149636.97,1.24QALYs) verus chemotherapy($13941.06,0.75QALYs) is $135695.91 and the QALYs is 0.49. ConclusionsEvidence suggests that Nivolumab plus chemotherapy a for the first-line treatment of locally advanced or metastatic gastric/GEJ/oesophageal adenocarcinoma may be not a cost-effective choice.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- First-Line Systemic Treatment Strategies for unresectable hepatocellular carcinoma : a cost-effectiveness analysis 97%
- Cost-effectiveness of real-world administration of chemotherapy and add-on Viscum album L. therapy compared to chemotherapy alone in the treatment of stage IV NSCLC patients 95%
- Survival benefit of adjuvant therapy following neoadjuvant therapy in patients with resected esophageal cancer: a retrospective cohort study 94%
Similar papers in this journal
- Circulating serum miRNAs predict response to platinum chemotherapy in high-grade serous ovarian cancer 92%
- Comprehensive analysis of potential immunotherapy genomic biomarkers in 1,000 Chinese patients with cancer 92%
- Sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors on new-onset overall cancer in type 2 diabetes mellitus: a population-based study 91%
Similar papers in this journal
- Hepatic resection versus transarterial chemoembolization for the intermediate stage hepatocellular carcinoma: A cohort study 91%
- Osthole Suppresses Prostate Cancer Progression by Modulating PRLR and the JAK2/STAT3 Signaling Axis 91%
- Meta-Analysis of Adenoviral p53 Gene Therapy Clinical Trials in Recurrent Head and Neck Squamous Cell Carcinoma 90%
Similar papers in this journal
- Efficacy of Lactococcus lactis strain plasma (LC-Plasma) in easing symptoms in patients with mild coronavirus disease 2019 (COVID-19): protocol for an exploratory, multicenter, double-blinded, randomized controlled trial (PLATEAU study) 92%
- Patterns of peritoneal dissemination and response to systemic chemotherapy in common and rare peritoneal tumors treated by cytoreductive surgery: Study protocol of a prospective, multi-center, observational study 92%
- Efficacy of clarithromycin on COVID-19 pneumonia without oxygen administration; protocol for multicenter, open-label, randomized-controlled, 3-armed parallel group comparison, exploratory trial (CAME COVID study) 92%
Similar papers in this journal
- Safety and Immunogenicity of the COVID-19 Vaccine BNT162b2 in Patients Undergoing Chemotherapy for Solid Cancer 92%
- Post COVID-19 condition of the Omicron variant of SARS-CoV-2 89%
- Effect of evacuation of Japanese residents from Wuhan, China, on preventing transmission of novel coronavirus infection: a modelling study 89%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.